Notable News to Watch: Lannett Company (NYSE:LCI)

Lannett Company (NYSE:LCI) spotted trading -42.31% off 52-week high price. On the other end, the stock has been noted 81.08% away from the low price over the last 52-weeks. The stock changed -3.21% to recent value of $6.03. The stock transacted 1904688 shares during most recent day however it has an average volume of 1023.93K shares. The company has 41.83M of outstanding shares and 28.57M shares were floated in the market.

On Aug. 27, 2019,  Lannett Company (NYSE:LCI)  reported that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, a wholly owned subsidiary of privately held Neolpharma Group.This agreement is separate and in addition to the supply and distribution agreement for Levothyroxine Sodium Tablets USP recently entered into by the companies.

Under the new agreement, Lannett will advise on a wide array of matters broadly related to assisting Cediprof and its affiliated entities with their efforts to further develop and commercialize products for the U.S. generic market.  Lannett will receive an advisory fee for its services.

We have formed a strong working relationship with Cediprof and look forward to providing our expertise and assistance to help Cediprof establish, in due course, an expanded presence in the U.S. generic drug market, said Tim Crew, chief executive officer of Lannett.  We bring a deep knowledge of the U.S. generic drug market, which Cediprof can leverage across its broad portfolio and operational footprint.

Our mutual desire is to further expand the relationship and, we eventually expect to commercialize for the U.S. market certain products in the oncolytic and hormonal therapeutic categories, including injectables, that are currently within Cediprof’s development and manufacturing capabilities.

Its earnings per share (EPS) expected to touch remained -29.70% for this year while earning per share for the next 5-years is expected to reach at 15.00%. LCI has a gross margin of 37.70% and an operating margin of -38.10% while its profit margin remained -39.80% for the last 12 months.

According to the most recent quarter its current ratio was 2.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -9.87% from the mean of 20 days, -4.23% from mean of 50 days SMA and performed -10.99% from mean of 200 days price. Company’s performance for the week was -14.47%, -8.22% for month and YTD performance remained 21.57%.

Leave a Reply

Your email address will not be published. Required fields are marked *